The global progressive fibrosing interstitial lung disease (PF-ILD) treatment market is witnessing robust growth, fueled by an alarming increase in interstitial lung diseases (ILDs), greater clinical awareness, and continuous innovation in diagnostics and therapies. In 2025, the PF-ILD treatment market is projected to be valued at USD 5,348.46 million and is anticipated to reach USD …